Good afternoon. Welcome to the 2026 Annual Meeting of Stockholders of BioMarin Pharmaceutical Inc. At this time, I would like to turn the conference over to Alexander Hardy, President and Chief Executive Officer of BioMarin. Please go ahead. On behalf of the entire board, our officers and employees, I want to welcome you all to the annual meeting of stockholders of BioMarin Pharmaceutical Inc. Our board annually considers the appropriate format of our annual meeting, and this year we decided to hold a virtual annual meeting. I am Alexander Hardy, President and Chief Executive Officer of BioMarin, and I will be presiding at this meeting. Eric Fleekop, Vice President and Deputy General Counsel of the company, will act as Secretary of this meeting. Within the virtual meeting platform, you will find a copy of the rules of conduct and procedures for the annual meeting. To conduct an orderly meeting, we ask that participants abide by these rules. Before proceeding with the meeting formalities, please note that I am reading from a script. For your information, the script helps ensure observance of legal formalities and a smooth flow of business at the meeting. I now call the meeting to order and recognize Mr. Fleekop. Mr. Hardy, I have a copy of the list of stockholders of record as of April 7th, 2026, the record date for this meeting, and a certificate attesting that such list has been made available for examination at BioMarin's public website at investors.biomarin.com for the 10 days immediately preceding this meeting. I also have a copy of the notice of meeting and an affidavit attesting that such notice was mailed on or about April 21st, 2026, to all stockholders of record as of April 7th, 2026. The original affidavit, together with the documents attached and the original certificate, should be annexed to the meeting minutes. Christina Perino, representing the Carideo Group, will act as the Inspector of Election of this meeting and any adjournments thereof, and she has subscribed an oath to execute faithfully her duties as voting inspector. Voting on the matters to be considered will be by ballot. For this purpose, stockholders who are on this conference call who wish to change their vote from their previously submitted proxies or who wish to vote during the annual meeting should vote in accordance with the instructions provided in BioMarin's proxy statement under the header "How do I vote?" Ms. Perino, will you please report on the number of shares of the company stock that are represented at the meeting? Mr. Hardy, the virtual meeting attendance has been canvassed, and I wish to report that there are present on this conference call, or represented by proxy, 175,813,292 shares of the company's common stock, representing approximately 90.96% of the shares that are issued, outstanding, and entitled to vote at this meeting. Such shares constitute a quorum for the transaction of business at this meeting. Thank you. As the holders of the majority of the shares entitled to a vote at this meeting are present either on this conference call or by proxy, I declare this meeting to be duly convened for purposes of transacting such business as may properly come before it. The polls are now open for voting. Stockholders who have submitted proxies or who have previously voted via the internet or by phone and who do not wish to change their vote do not need to take further action. Their votes will be counted automatically. The next order of business is a description of the matters to be voted on at today's meeting. There are four proposals to be considered by stockholders at this meeting. The matters to be voted on at this meeting are listed in the proxy statement relating to this meeting. We will vote after all items have been presented. When the report of the inspector of the election is complete, we will announce the results. Stockholders who wish to ask a question regarding any of the proposals may do so by submitting the question in writing where indicated on the webcast portal for this meeting in accordance with the rules of conduct and procedures. Only stockholders will be permitted to submit questions. We will do our best to respond to the questions received in the time permitted. The first proposal before the stockholders of the corporation is the election of 10 directors to serve on the company's board of directors. Pursuant to the company's bylaws, the board has nominated me, Alexander Hardy, Elizabeth Anderson, Barbara Bodem, Ian Clark, Athena Countouriotis, Willard Deer, Mark Enyedy, Maykin Ho, Robert J. Hombach, and Timothy Walbert, each to serve as a director of the company until the next annual meeting of the stockholders or/and until his successor or her successor shall be elected and shall qualify. There being no other nominations, the nominations are hereby closed. The second proposal before the stockholders is the ratification of the selection by the board of KPMG LLP as BioMarin's independent registered public accounting firm for the year ending December 31st, 2026. The third proposal before stockholders is an advisory vote on the compensation of the company's named executive officers, as disclosed in the proxy statement relating to this meeting. The stockholders have been asked to vote on an advisory basis on the following resolution. Resolved, that the company's stockholders hereby approve, on an advisory basis, the compensation of the company's named executive officers, as disclosed in the proxy statement pursuant to the compensation disclosure rules with the SEC, including the compensation discussion and analysis, compensation tables, and narrative discussion and any related material. The fourth proposal before the stockholders is the approval of an amendment to the company's 2017 Equity Incentive Plan, as amended. I will now take a moment to check if any questions regarding today's proposals have been submitted online. After the formal part of the meeting, there will be also an opportunity for Q&A on general matters other than the four proposals under consideration at this meeting. No questions regarding today's proposals were submitted online. We will now continue the meeting. At this point, I declare the polls now closed. I would like to call Ms. Perino to report on her tabulation of the vote. Mr. Hardy, the results of the voting on the matters considered at this meeting are as follows. Proposal number one, election of directors. A majority of the shares of common stock cast that were entitled to vote and represented at this conference call, or by proxy at this meeting, were voted for the election of each of Elizabeth M. Anderson, Barbara W. Bowden, Ian T. Clark, Athina Koutourakis, Willard Deer, Mark Enyedi, Alexander Hardy, Macon Ho, Robert J. Hombach, and Timothy P. Walpert as a director of the company. Proposal number two, ratification of KPMG LLP. Majority of the shares of common stock cast that were entitled to vote and represented on this conference call, or by proxy at this meeting, were voted for the ratification of the selection of KPMG LLP by the directors as BioMarin's independent registered public accounting firm for the year ending December 31, 2026. Proposal number three, advisory vote on executive compensation. A majority of the shares of common stock cast that were entitled to vote and represented on this conference call, or by proxy at this meeting, were voted for the approval on an advisory basis of the compensation of the company's named executive officers as disclosed in the proxy statement relating to this meeting. Proposal number four, approval of an amendment of the 2017 Equity Incentive Plan, as amended. A majority of the shares of common stock cast that were entitled to vote and represented on this conference call, or by proxy at this meeting, were voted for the approval of the amendment to the company's 2017 Equity Incentive Plan, as amended. Based on the reported results, I declare that all of the director nominees have been elected and proposal numbers two, three, and four have been approved. A full tally of the final voting results will be published in a report on Form 8-K, which will be filed with the Securities and Exchange Commission within four business days of this meeting. The meeting is adjourned. If you would like more information about BioMarin's recent developments, I invite you to review our investor corporate presentations available on our public website, investors.biomarin.com, under the Events and Presentations. I will now take a moment to check if any questions have been submitted online in accordance with the rules of conduct and procedures, and I will answer appropriate questions within the time permitted. Jason Trimborne of KPMG LLP, BioMarin's independent auditor, is also on the conference call and available to respond to appropriate questions submitted online. No questions were submitted online, we will now end the meeting. Thank you for your support of BioMarin and for attending the annual meeting. Goodbye. This now concludes the meeting. Thank you for joining, and have a pleasant day.